Open Access

Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results

Lawrence Bonne
Lawrence Bonne
, 
Chris Verslype
Chris Verslype
, 
Annouschka Laenen
Annouschka Laenen
, 
Sandra Cornelissen
Sandra Cornelissen
, 
Christophe M. Deroose
Christophe M. Deroose
, 
Hans Prenen
Hans Prenen
, 
Vincent Vandecaveye
Vincent Vandecaveye
, 
Eric Van Cutsem
Eric Van Cutsem
 and 
Geert Maleux
Geert Maleux
   | Feb 22, 2017
Radiology and Oncology's Cover Image
About this article
Previous Article
Next Article
Cite
Article Category: Research Article
Published Online: Feb 22, 2017
Page range: 74 - 80
Received: Dec 23, 2016
Accepted: Jan 12, 2017
DOI: https://doi.org/10.1515/raon-2017-0007
Keywords
© 2017 Lawrence Bonne, Chris Verslype, Annouschka Laenen, Sandra Cornelissen, Christophe M. Deroose, Hans Prenen, Vincent Vandecaveye, Eric Van Cutsem, Geert Maleux
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

A 63-year-old male patient presented with a carcinoid of the lung and diffuse bilobar liver involvement. (A) Portal venous phase contrast-enhanced CT-scan confirms diffuse metastatic involvement of both liver lobes (white arrowheads at the level of the largest metastasis in the left liver lobe; black arrows at the level of multiple smaller lesions in the right liver lobe); Selective angiogram of the left hepatic artery (B) before and (C) after chemoembolization with doxorubicin-eluting SAP-microspheres (arrow at the level of the micro-catheter in the left hepatic artery); Selective angiogram of the celiac trunk (D) before and (E) after chemoembolization with doxorubicin-eluting SAP-microspheres (arrow shows stasis of contrast at the level of the right hepatic artery); (F) Portal venous phase contrast-enhanced CT-scan 10 weeks after initial chemoembolization shows marked decrease in volume and enhancement of most of the metastatic lesions in left and right liver lobes.
A 63-year-old male patient presented with a carcinoid of the lung and diffuse bilobar liver involvement. (A) Portal venous phase contrast-enhanced CT-scan confirms diffuse metastatic involvement of both liver lobes (white arrowheads at the level of the largest metastasis in the left liver lobe; black arrows at the level of multiple smaller lesions in the right liver lobe); Selective angiogram of the left hepatic artery (B) before and (C) after chemoembolization with doxorubicin-eluting SAP-microspheres (arrow at the level of the micro-catheter in the left hepatic artery); Selective angiogram of the celiac trunk (D) before and (E) after chemoembolization with doxorubicin-eluting SAP-microspheres (arrow shows stasis of contrast at the level of the right hepatic artery); (F) Portal venous phase contrast-enhanced CT-scan 10 weeks after initial chemoembolization shows marked decrease in volume and enhancement of most of the metastatic lesions in left and right liver lobes.

(A) Kaplan-Meier overall survival estimate shows an overall survival (with 95% confidence interval) at 12, 24 and 36 months after TACE of 67% (lower limit 38% - upper limit 85%), 47% (lower limit 21% - upper limit 69%) and 32% (lower limit 11% - upper limit 56%); (B) Kaplan-Meier overall survival estimate shows an overall survival (with 95% confidence interval) at 5, 10 and 15 years after diagnosis of 53% ( lower limit 26% - upper limit 74%), 18% (lower limit 3% - upper limit 41%) and 18% (lower limit 3% - upper limit 41%).
(A) Kaplan-Meier overall survival estimate shows an overall survival (with 95% confidence interval) at 12, 24 and 36 months after TACE of 67% (lower limit 38% - upper limit 85%), 47% (lower limit 21% - upper limit 69%) and 32% (lower limit 11% - upper limit 56%); (B) Kaplan-Meier overall survival estimate shows an overall survival (with 95% confidence interval) at 5, 10 and 15 years after diagnosis of 53% ( lower limit 26% - upper limit 74%), 18% (lower limit 3% - upper limit 41%) and 18% (lower limit 3% - upper limit 41%).

Procedure-related toxicity

Toxicitygradenumber of patientspercentage (%)
Ischemic cholecystits316
Carcinoid storm216
Insulin storm216
Postembolization syndrome 21482  

Patients’ demographic data

VariableNumber
Number of patients included17
Age (years)      
      Mean56
      SD13.9
      Range18–82
Sex      
      M8
      F9
Primary tumour      
      Intestinal NET6
      Pancreatic NET2
      Pulmonary NET2
      Pancreatic insulinoma4
      Unknown3
Surgical resection of primary tumour      
      Intestinal NET5
      Pancreatic NET2
      Pulmonary NET2
      Pancreatic insulinoma1
      Total10
Tumour grade (Ki-67 index)      
      Ki-67 < 2%4
      Ki-67 2–20%6
      Ki-67 > 20%4
      Unknown3
Tumour burden (% of total liver volume)      
      0–10%4
      10–20%3
      20–50%5
      > 50%5
Extrahepatic metastatic disease16
      Lymphadenopathy7
      Bone5
      Lung3
      Spleen1
      Adrenal3
      Brain1
      Ovary2
      Pancreas2
      Peritoneum1
      Skin1
Previous treatment      
      Surgical resection of liver metastases1
      Radiofrequency ablation of liver metastases1
      Radiotherapy for brain metastases1
      Radiotherapy for bone metastases1
      Interferon3
      Everolimus7
      m-TOR-inhibitor1
      Sunitinib4
      Somatostatine analogue15
      Diazoxide3
eISSN:
1581-3207
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Radiology, Internal Medicine, Haematology, Oncology
Journal RSS Feed